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Abstract
Mammography screening for breast cancer is widely available in many countries. Initially praised as a universal
achievement to improve women's health and to reduce the burden of breast cancer, the benefits and harms of
mammography screening have been debated heatedly in the past years. This review discusses the benefits and harms
of mammography screening in light of findings from randomized trials and from more recent observational studies
performed in the era of modern diagnostics and treatment. The main benefit of mammography screening is reduction
of breast-cancer related death. Relative reductions vary from about 15 to 25% in randomized trials to more recent
estimates of 13 to 17% in meta-analyses of observational studies. Using UK population data of 2007, for 1,000 women
invited to biennial mammography screening for 20 years from age 50, 2 to 3 women are prevented from dying of
breast cancer. All-cause mortality is unchanged. Overdiagnosis of breast cancer is the main harm of mammography
screening. Based on recent estimates from the United States, the relative amount of overdiagnosis (including ductal
carcinoma in situ and invasive cancer) is 31%. This results in 15 women overdiagnosed for every 1,000 women invited
to biennial mammography screening for 20 years from age 50. Women should be unpassionately informed about the
benefits and harms of mammography screening using absolute effect sizes in a comprehensible fashion. In an era of
limited health care resources, screening services need to be scrutinized and compared with each other with regard to
effectiveness, cost-effectiveness and harms.
Introduction
The verb 'to screen' is defined as 'to sift by passing
through a screen' [1]. 'To 'sift'; derives from an old Dutch
word ('zeef'); a 'utensil consisting of a circular frame with
a finely meshed or perforated bottom, used to separate the
coarser from the finer particles of any loose material' [1].
The definitions of screening vary among different cultures,
settings, and time periods [2,3]. In general, all definitions of
screening include an identification of disease or disease pre-
cursor among presumptively healthy individuals. There are
mainly two different approaches of cancer screening: pre-
vention of disease by finding and removing premalignant
precursors of cancer; and early detection of cancer where
the goal is to treat the invasive cancer in an early curable
stage [4]. In 1968, the World Health Organization suggested
10 principles that should be fulfilled before implementing
screening in a population (Table 1) [5]. Some of the princi-
ples regard knowledge about biologic development of cancer
(principles 4 and 7).
Screening for breast cancer with mammography aims at
detecting breast cancer at an early, curable stage. For early
detection by screening to be beneficial, we anticipate a
continuous, linear growth pattern of tumors, and that
breast cancer has not spread at the time when tumors are
detectable at mammography. Thus, if the assumptions of
tumor growth are not correct or if growth of tumors is
heterogenic, screening mammography might not be an
adequate tool to reduce the burden of breast cancer [6].
The idea of early detection started in the US in the early
20th century with educational mass campaigns where the
message of 'do not delay' seeking medical help for a variety
of cancer signs and symptoms was central [7]. However,
none of these early campaigns had an effect on the mor-
tality of breast cancer [8]. In 1963 the first randomized
trial of mammography screening was launched within the
Health Insurance Plan in New York [8], and several other
trials followed [9]. Most of the trials were performed be-
fore widespread use of anti-estrogens and modern chemo-
therapy with the exception of the Canadian National
Breast Screening Study and the age trial [10,11].
In contrast to other cancer screening tools, mammog-
raphy screening was evaluated in randomized trials before it
was widely recommended and implemented. Nevertheless,
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there has been a continuous discussion of mammography
screening, which started in full in 2000 after a Cochrane re-
view of the randomized trials indicated little effect of screen-
ing [12]. More recently, the effect of mammography
screening outside the experimental setting, in the modern
era with improvements in awareness, diagnostics, and treat-
ment, has been discussed [13,14].
The mammography debate has not only been about the
beneficial effects of mammography screening, but more
recently also the harms. In the last 10 years increasing
awareness of overdiagnosis in mammography screening
has emerged. Overdiagnosis is defined as the detection of
tumors at screening that might never have progressed to
become symptomatic or life-threatening in the absence of
screening. This is a direct harm of screening because
markers to distinguish the overdiagnosed tumors from the
potential life-threatening tumors are lacking and, thus, all
tumors are treated. Women with overdiagnosed tumors
only experience the harms and side effects of treatment,
without any benefit. In this review we discuss the benefits
and harms of mammography screening and give an over-
view of the findings from randomized trials and from
more recent observational studies from the era of modern
diagnostics and treatment. We aim at presenting the bene-
fits and harms per 1,000 women invited to mammography
screening who started screening at age 50 years and were
screened every second year until age 69 years; screening of
this age group has been shown to achieve most of the
benefit with less harm [15,16].
Screening mammography
Attendance rates
Mammography screening is recommended (and in Europe
offered through organized programs) in most Western
countries. However, in Switzerland an independent panel
of experts (the Swiss Medical Board) reviewed the evidence
on mammography screening and concluded that harms out-
weighed the benefits and recommended against mammog-
raphy screening [17]; that is, that screening programs
should not be implemented in areas where such programs
do not exist and that the ongoing programs should be
phased out. When screening is recommended, the eligible
age range differs in different countries from 40 to 74 years
[4,18,19]. The recommended interval between two screens
varies from 1 to 3 years [18]. Mammography screening is
well accepted; on average, more than half of eligible women
attend screening mammography. In most countries, attend-
ance rates are higher than 70%. Women aged 50 to 69 years
have the highest attendance rate [18,19]. The attendance
rate varies between countries (19.4% to 88.9%), and in differ-
ent age groups. Most women who have participated once
continue to participate.
False positive tests
As with every diagnostic test the sensitivity and specifi-
city of mammography screening are not perfect; various
levels of sensitivity and specificity for detecting breast
cancer have been published [20,21]. The risk of experi-
encing a false positive mammogram for women under-
going biennial screening from age 50 to 69 years in
Europe is about 20% [21], and the risk of experiencing a
biopsy due to a false positive test is 3% [21]. Based on
data from the UK, 2.3% of all women with a false posi-
tive test had a lumpectomy, representing 76 out of
100,000 women screened in one screening round [22].
The risk is even higher in the US, where the 10-year
false positive rate is 30%, and 50% of all women will ex-
perience a false positive mammogram at one time
[23,24]. The challenges with a false positive test, apart
from the monetary costs, are impaired psychological
well-being and changes in health behavior among
women with the false positive test. After 6 months, only
64% of those recalled due to a false positive test were
declared cancer-free; after 1 year approximately 90%
were declared cancer-free, and only after 2 years were
all those who were in fact free of cancer declared
cancer-free [25]. Research has shown that false positive
results negatively influence women's psychological well-
being during the period immediately after the tests, and
a recent study showed that women with false positive
findings experience psychological harm for at least
3 years after screening [26]. Women with false positive
findings had higher use of health care services; 55% of
women who experienced a positive recall returned to
the outpatient clinic in the first year after screening,
some up to eight times [27], and reported lower quality
of life than those without [27,28]. Some women may
also have altered health behavior and trust in the health
care system [28].
Table 1 The World Health Organization’s 10 principles of
screening
1. The condition sought should be an important health problem
2. There should be an accepted treatment for patients with recognized
disease
3. Facilities for diagnosis and treatment should be available
4. There should be a recognizable latent or early symptomatic stage
5. There should be a suitable test or examination
6. The test should be acceptable to the population
7. The natural history of the condition, including development from
latent to declared disease, should be adequately understood
8. There should be an agreed policy on whom to treat as patients
9. The cost of case-findings (including diagnosis and treatment of
patients diagnosed) should be economically balanced in relation to
possible expenditure on medical care as a whole
10. Case finding should be a continuing process and not a 'once and
for all' project
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False negative tests
Interval cancers are cancers detected after a normal
screening mammogram and before the next scheduled
mammogram. Interval cancers either were overlooked
at the last mammogram or are rapidly growing cancers
that become apparent in the screening interval [29]. In a
re-interpretation of interval cancers, around 35% were
overlooked [30], while 65% were not visible at the latest
mammogram and appeared in the interval between
screening mammograms. Of all breast cancers detected
among women who participate in screening, 28 to 33%
are interval cancers [20], and this proportion seems to
be stable in the different screening rounds [29]. Use of
digital mammography is increasing, and detection rates
of ductal carcinoma in situ (DCIS) and invasive cancers
are higher. Whether this will decrease the proportion of
interval cancers is unknown, but the rate of missed can-
cers seems to be similar to that of analogue, screen-film
mammography [31]. One might anticipate, therefore,
that the proportion of interval cancers with digital
mammography will be comparable to that with analogue
screen-film mammography. However, the increasing de-
tection rates with digital mammography might increase
the amount of overdiagnosis.
Women diagnosed with interval cancer do not benefit
from early detection, but could be falsely reassured by
their last normal mammogram and delay seeking med-
ical care. However, this might not seem to be the case as
women with interval cancer do not have poorer progno-
sis than women who chose not to utilize mammography
screening [29].
For 1,000 women invited to mammography screening
every second year for 20 years from age 50, 200 will ex-
perience a false positive mammogram, 30 will undergo a
biopsy due to a false positive mammogram, and 3 will be
diagnosed with interval cancer [32,33] (Figure 1).
Figure 1 Summary of benefits and harms when 1,000 women are screened every second years for 20 years starting at age 50. Number
of women with false positive mammograms and false positive biopsies are based on a review [32]. Number of interval cancers are based on
reported number of interval cancer in the National Health Service breast screening programme [33]. The numbers of overdiagnosed and
prevented breast cancer deaths are estimated based on 31% overdiagnosis [19] and 13 to 17% reduction in mortality from breast cancer [35].
These relative numbers are applied to the observed incidence of invasive breast cancer (women aged 50 to 69 years) and mortality (women
aged 55 to 74 years) in the UK in 2007 [32]; this resulted in 15 overdiagnosed women and 2 to 3 prevented breast cancer deaths per 1,000
women. No deaths are prevented overall [9].
Løberg et al. Breast Cancer Research  (2015) 17:63 Page 3 of 12
Overdiagnosis
Mammography screening inevitably entails increased
breast cancer incidence [36] due to earlier detection of
cancers that would otherwise have been diagnosed later in
life and due to diagnosis of cancers that would not have
been identified clinically in someone's remaining lifetime.
The latter category is commonly referred to as overdiag-
nosis. Theoretically, overdiagnosis can occur because the
tumor lacks potential to progress to a clinical stage, or
even regresses [37], or because the woman dies from other
causes before the breast cancer surfaces clinically. In real-
ity, these three alternatives cannot be reliably disen-
tangled. In any of the three scenarios the individual
woman would be diagnosed and treated with no possible
survival benefit. Hence, overdiagnosis represents a sub-
stantial ethical dilemma and burdens the patient and the
health care system. Treatment for breast cancer includes
surgery, radiotherapy, chemotherapy, and antiestrogen
treatment. Risk of death from cardiovascular disease is
increased in women treated with radiotherapy [38], and
adjuvant treatment may be cardiotoxic (for example, tax-
anes, anthracyclines, or trastuzumab) [39]. It is possible
that overtreatment causes increased mortality by other
causes besides breast cancer. This may explain why there
is no reduction in measurable overall mortality with
screening mammography [9] (Figure 2).
Overdiagnosis does apply to both carcinoma in situ
and invasive cancer; the lifetime risk of progression of
carcinoma in situ to invasive breast cancer is unknown,
but probably less than 50%; [40] and the lead-time is
longer for in situ than invasive cancers. Thus, it is logical
and intuitive that carcinoma in situ can be overdiag-
nosed. However, pathological verified invasive cancers
can also be overdiagnosed. This contradicts what most
clinicians were taught in medical school, and can be
hard to understand for both clinicians and the public.
One way of looking at this challenge is by using the 'ice-
berg model' [40]: the development of cancer is a lengthy
and complex process, where unrepaired genetic instabil-
ity and changes in tumor microenvironment could lead
to distinct, heterogeneous subpopulations of abnormal
cells. Cancer can be envisioned as an iceberg of disease,
where the visible tip above the waterline comprises the
most aggressive lesions - those that produce symptoms
and clinical disease. The majority of our body of know-
ledge concerning the natural history of malignancies
Figure 2 Scenarios for different outcomes of screening mammography. (A) Screening is ineffective. (B) Screening is effective. (C) Screening
leads to overdiagnosis. (D) Screening leads to overdiagnosis that causes death from side effects of treatment.
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comes from observations from these 'top-of-the-iceberg',
symptomatic lesions above the waterline [40]. Under-
neath the water's surface, however, there might be mul-
tiple, indolent cancer subpopulations of cells. These
subpopulations will look like cancer to the pathologist if
detected through screening [40]. Early detection (such as
mammography screening) dives under the surface and
picks up silent lesions. The natural history of these
asymptomatic lesions has not been studied and is there-
fore essentially unknown, but many of these may be in-
dolent over time and never generate symptoms or
disease without screening.
Estimates of overdiagnosis
Precise estimation of overdiagnosis is a complicated and
difficult task. There is no perfect analysis that would be
universally applicable to this problem. Consequently, re-
cent studies show a large variation in the estimated over-
diagnosis of breast cancer, from none to 54% [41]. In
studies based on statistical modeling to adjust for lead-
time, estimates of overdiagnosis are consistently below
5% [42,43]. In contrast, observational studies have pub-
lished higher estimates, between 22 and 54% [37,41,42],
depending on the use of the denominator [44]. In
Table 2, we present the amount of overdiagnosis and re-
duction in mortality estimated with different denomina-
tors (incidence/death from breast cancer in different age
groups). It clearly shows that different denominators
(rows 2 to 4 in Table 2) result in different amounts of
overdiagnosis and mortality reduction. Thus, it is im-
portant that benefits and harms of mammography
screening are presented using similar denominators (in
Table 2).
Overdiagnosis might be underestimated in the statistical
modeling studies because they tested only one assumption
at a time, based either on assumptions for the risk of pro-
gression from carcinoma in situ to invasive cancer [42], or
on sojourn time with adjustment for lead-time [42,43]. In
statistical models based on sojourn time and lead-time,
overdiagnosis has been disregarded in the estimation of
lead-time, since the assumption of growth has been based
on a progressive disease. This, however, is not the case for
overdiagnosis where the disease is non-progressive or per-
haps even regressive [37]. Thus, when using these esti-
mates, overdiagnosis is likely to be underestimated [48].
Since we do not have any direct, biological evidence of
non-progression or regression of breast cancer, assump-
tions cannot easily be tested, and represent only a 'guess'.
Evidence from observational studies is more convincing.
The difference in the estimates from observational studies
(22 to 54%) might be due to different assumptions of ex-
pected changes in breast cancer incidence due to changes
in breast cancer risk factors, different follow-up time after
introduction of screening, and differences in accounting
for lead-time. After 25 years of follow-up, the Canadian
National Breast Screening Study [10], comparing physical
breast examination with combined physical breast exam-
ination and annual mammography in women aged 40 to
59 years, found an excess of invasive cancer in the screen-
ing arm, resulting in 22% overdiagnosis. When the num-
ber of breast cancers detected at screening is used as the
denominator (as in the Canadian study), the amount of
overdiagnosis observed in the previous randomized trials
is strikingly similar (22 to 24%) [10,49] and in line with
the 30% reported in the Cochrane review of screening for
breast cancer with mammography [9]. The amount of
overdiagnosis might even be higher because DCIS, which
accounts for one out of four breast cancers detected at
mammography screening, was not included in these esti-
mates [10]. If DCIS is a precursor of invasive breast can-
cer, we would expect a drop in incidence of invasive
breast cancer after detection and removal of DCIS. There
is no evidence for this. On the contrary, incidence rates
keep increasing in countries with mammography screen-
ing [50].
Given the uncertainty of the estimates from modeling
and observational studies, we used the best available esti-
mate of overdiagnosis from observational data from a US
study where DCIS and invasive cancer were included,
follow-up was more than 25 years after screening was ini-
tiated and no extensive untestable assumptions were made
[19]. However, in the US there is no mammography
screening program, and the rate of false positives is higher
than in Europe and Australia. Thus, it might be possible
Table 2 Different percentages of overdiagnosis and mortality reduction based on the number of cancers
overdiagnosed and deaths avoided from breast cancer using different denominators (incidence/death from breast
cancer in different age-groups) in Norway in 2010
Age (years) Expected number
of cancers
Percentage of overdiagnosis
(n = 714.4)
Expected number of
breast cancer deaths
Percentage of mortality
reduction (n = 53.7)
50-99 2,208 19.4 693 7.8
50-79 1,571 27.3 506 10.6
50-69 942 45.5 334 16.1
The expected number of breast cancers and breast cancer deaths is estimated as the observed incidence and mortality rates in Norway from 1980 to 1984
multiplied by the Norwegian female population in 2010 [45-47]. The number of overdiagnosed cancers (714.4 cancers) is based on studies by Falk and coworkers
[45] and Kalager and coworkers [44] and the number of reduced breast cancers (53.7 avoided deaths from breast cancer) is estimated by reducing the number of
expected (358) breast cancer deaths by 15% in the age group 55 to 74 years (358 × 0.15 = 53.7).
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that the amount of overdiagnosis differs between the US
and Europe and Australia. Since none of the estimates of
overdiagnosis from Europe or Australia were based on
follow-up as long as in the US study, we choose to use the
US estimate of 31% overdiagnosis (in line with what is ob-
served in the randomized trials) [19]. We estimated the
number of overdiagnosed women based on the observed
incidence of invasive breast cancer in women aged 50 to
69 years in the UK in 2007 [19,34,49]. For 1,000 women
invited to biennial mammography screening for 20 years
from age 50, 15 will be overdiagnosed (Figure 1). Based on
different meta-analyses and reviews of benefits and harms
of mammography screening [9,22,32] and our best esti-
mate [19,34,35], we present a figure showing the different
estimates of overdiagnosis and prevented deaths from
breast cancer (Figure 3).
To be able to differentiate between potential lethal and
non-lethal cancers, experimental studies have to be per-
formed, preferably as an interdisciplinary cooperation be-
tween the biomedical and clinical communities. First,
however, one has to accept that overdiagnosis does occur,
and perhaps also change the terminology of non-lethal can-
cer to 'IDLE tumor' (InDolent Lesions of Epithelial origin),
as recently suggested [6].
Breast cancer mortality
According to the randomized breast cancer screening
trials, the relative reduction in mortality from breast
cancer ranges between 15 and 25% [9,22,36,51] for
women aged 50 to 69 years. The differences in these
estimates are due to differences in inclusion of random-
ized trials in pooled estimates. For the 25% estimated
Figure 3 Different estimates of overdiagnosed women and saved lives from breast cancer in different meta-analyses and trials.
Euroscreen: estimates derived from a review of observational studies, where estimates of mortality reduction from case–control studies are
included [32]. UK Independent review: estimates on relative effect derived from randomized trials of mammography screening and applied to UK
national rates for women aged 55 to 79 years [22]. UK Observational: estimates based on 31% overdiagnosis [19] and 13 to 17% reduction in
mortality from breast cancer [35] and applied to the observed incidence of invasive breast cancer (women aged 50 to 69 years) and mortality
(women aged 55 to 74 years) in the UK in 2007 [34]; this resulted in 2 to 3 prevented deaths from breast cancer. Cochrane review: estimates
from the randomized trials of mammography screening [9]. The Cochrane review does not assume the effect of mammography screening to last
for 20 years as is assumed in the other estimates, but relates to what was observed in the randomized trials [9].
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reduction, mammography screening versus no-screening
is compared; thus, the Canadian trial was not included
because they compared physical breast examination to
combined physical breast examination and annual mam-
mography [10,36]. For the 15% estimated reduction,
methodological limitations in some of the randomized
trials was accounted for [9]; without this 'adjustment', a
20% reduction was found [9,22,52]. None of the ran-
domized trials showed any effect on cancer mortality or
all-cause mortality [9]. Given the number of women
enrolled in the randomized trials (660,000) and a 20%
reduction in breast cancer mortality, a 2% reduction in
all-cause mortality should have been detectable [52].
The absence of a reduction in all-cause mortality indi-
cates that women die of other diseases at about the same
time in life with and without screening.
Study designs
There are a number of methods to investigate the effect of
mammography screening in a non-experimental setting. Co-
hort studies, case–control studies, and trend studies show
different estimates of mortality reduction, ranging from no
effect to 50% reduction in breast cancer mortality [53,54].
Cohort studies
The optimal non-experimental design to investigate the
effect of mammography screening is a cohort study of
women invited and women not-invited to mammography
screening who have similar baseline risk for breast cancer
and breast cancer death and similar opportunities for opti-
mal breast cancer treatment. Only few such studies exist,
and the estimated effect of mammography screening on
breast cancer mortality varies from 10 to 25% reduction
[35]. A pooled estimate of these trials showed a reduction
in breast cancer mortality of 13 to 17% [35].
Case–control studies
In case–control studies (sometimes called case-referent
studies) cases are women who die of breast cancer and con-
trols are women who are alive stratified by whether they
have undergone screening mammography or not. Thus,
these studies when performed in settings where mammog-
raphy screening is recommended or where screening pro-
grams exist are comparisons of women who participate and
who do not participate in mammography screening. The
validity of these studies is low because of healthy screenee
and self-selection bias, as women with breast cancer are not
eligible to mammography screening or to be continued to
be screened (selection of the most healthy), and women
who choose to participate in mammography screening (se-
lection) may differ with regard to risk of death from those
who do not participate [55]. Attempts to adjust for these
biases have been done by adjusting for the relative risk in
breast cancer mortality between the non-participants and
the non-invited comparison group [7,56]. The underlying
assumption of these adjustments is that we do know the risk
of uninvited women. In randomized trials, we can easily find
the risk of breast cancer death for those not invited to
mammography screening (the control group). However, in
observational studies where everybody is invited or recom-
mended to undergo mammography screening, we have to
make assumptions on risk of death from breast cancer
among the uninvited women. These assumptions cannot be
tested and are therefore based on 'best guess' estimates. In
case–control studies, a 50% reduction in mortality from
breast cancer is found, and similar reductions are found in
cohort studies of participants and non-participants in mam-
mography screening [54,57]. When the randomized trial
from Malmö was analyzed as a case–control study, a 58%
reduction in mortality from breast cancer was found,
whereas the real, observed reduction in the trial was only
4% (8% when the results were adjusted for non-compliance
and contamination) [36]. Thus, estimates from case–control
studies systematically overestimate the effect of screening.
Trend studies
Trend studies are studies of population-based breast cancer
mortality over time in different ages (age-standardization)
and geographic areas. Data on population-based breast can-
cer mortality are easy to retrieve, but as the yearly mortality
rate is not reflective of time of diagnosis, deaths from breast
cancer diagnosed before invitation influences the mortality
rate some years after screening is implemented. Further,
when all eligible women are invited and a screening pro-
gram has been running for some time, the mortality rate is
expected to reach a steady state and further reduction can-
not be expected. After 7 years of follow-up in the Health
Insurance Plan study, the mortality reduction was no longer
apparent [58], indicating that screening has no effect if no
longer offered. For a continuing program, however, the
mortality effect will not disappear, but reach a steady state.
Thus, in the first years after screening has been introduced
and reached full coverage in the area studied, the cause of
change in trends of breast cancer mortality can be difficult
to study and interpret. Most trend studies show that breast
cancer mortality has declined in most European countries
since the early to mid-1990s. The decline in mortality is
even higher among women younger than the eligible age
range for screening and for some countries a reduction is
observed also for women older than the eligible age range
[59]. The interpretation of these results could be that
heightened awareness and improved therapy rather than
mammography screening are responsible for the observed
reduction [53,59,60].
Tumor stage
Another benefit of mammography screening could be
that breast cancers detected at screening are smaller and
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thus less advanced than those detected clinically. In gen-
eral, smaller tumors are more likely to be resected by
lumpectomy, and with less node-positive disease, less
adjuvant therapy is needed. Based on the randomized
mammography screening trials, however, this is not the
case; screening was associated with an increase in the
number of mastectomies of about 20% [9]. The reason is
that mammography increased both the number of
women diagnosed with invasive breast cancer and the
number found to have multiple microscopic cancers dis-
tributed throughout the breast, for which mastectomy is
recommended. Further, in the National Health Service
breast screening program in the UK, 30% of DCIS and
24% of invasive breast cancers were treated with mastec-
tomy, so earlier detection does not necessarily mean less
aggressive treatment [61]. As mentioned above, another
benefit of mammography screening could be less aggres-
sive adjuvant therapy, due to smaller and less aggressive
tumors. As seen in the stage distribution in screening
and non-screening groups in Norway [41], screening led
to the diagnosis of 58% more stage I (localized cancer)
and 22% more stage II (regional cancer or cancer involv-
ing the lymph nodes) cancers, without any reduction in
advanced stage disease (stages III and IV). Since all these
patients receive surgery (either mastectomy or breast-
conserving surgery with radiation) and most stage II
patients are recommended to receive adjuvant chemo-
therapy, screening may have led to 58% more women
undergoing breast surgery and 22% more women under-
going adjuvant chemotherapy [41]. Thus, screening
mammography does not seem to reduce the burden of
receiving more aggressive treatment.
Cause of death
The number of women saved from breast cancer death
might be outweighed by death from other causes due to
harms of treatment; however, due to uncertainty about
the overall number of women saved, we present differ-
ent estimates of women saved from breast cancer in dif-
ferent meta-analyses of randomized and observational
studies of breast cancer [19,22,32,34,35] (Figure 3). The
number needed to be invited to mammography to save
or harm women is highly dependent on the underlying
risk of breast cancer or death from breast cancer
(Figures 4 and 5, showing risk of breast cancer and
death from breast cancer in the US and UK [49,62]). In
the estimates shown in Figure 1, we use UK data from
2007 for mortality from breast cancer in women aged
Figure 4 Benefit and harm with screening mammography and use of aspirin over 10 years [62]. Shown are the 10-year risk of death from
breast cancer (bars above 0) and the 10-year risk of the diagnosis of breast cancer (bars below 0) among women aged 40 years and 50 years, with and
without mammography screening. Also shown are the 10-year risk of death from cancer (bar above 0) and the 10-year risk of major extracranial
bleeding, defined as bleeding necessitating transfusion or resulting in death (bar below 0), associated with the use or non-use of aspirin as a primary
preventive measure (on the basis of findings from randomized trials). In each pair (no screening versus screening and no aspirin versus aspirin), the
difference between the percentages represented by the bars shows the absolute benefit or harm associated with screening mammography or the use
of aspirin. Background data are derived from the literature.
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55 to 74 years [34], and the relative reduction of 13 to
17% in breast cancer mortality based on a meta-analysis
of observational studies [35]. For 1,000 women invited
to mammography screening every second year for 20
twenty years from age 50, 2 to 3 women are prevented
from dying from breast cancer (Figure 1).
Information to women
Screening differs from clinical practice. Individuals who
undergo a screening procedure are invited to participate
with the implied expectation that they will benefit. This
contrasts with clinical practice, where the patients ap-
proach the medical practitioner with a symptom or com-
plaint for help [3]. Thus, it is of utmost importance that
information about benefits and harms of mammography
screening is balanced. However, the harms of screening
have not been communicated to the public as well as the
benefits [63,64]. With increasing evidence of overdiagno-
sis, this is of concern and violates the individual's possi-
bility to make an informed choice.
However, proper information on risks and benefits is
not easy. Firstly, how do clinicians communicate benefits
and harms? The use of relative risks may suggest greater
effects than exist, whereas the use of absolute risks (or
equivalents, such as the number needed to screen) pre-
vents this misunderstanding. The use of relative risks
should be avoided or employed only in combination
with more comprehensible forms of communicating risk,
such as absolute risks or numbers needed to screen [65].
Secondly, many cannot interpret numbers as well as
words and have difficulty understanding numerical
expressions of risk [66]. In medical schools, courses in
statistics usually do not go far enough in teaching statis-
tical or probabilistic thinking, and few teach strategies
for effective communication. Hence, most physicians are
poorly equipped to discuss risk factors in a way that is
readily comprehensible to their patients. This deficiency
puts the ideal of informed consent in jeopardy [65,67].
Framing is the presentation of logically equivalent infor-
mation in different forms. Positive framing emphasizes
Figure 5 Twenty year risk for diagnosis of, and death from, breast and prostate cancer with and without screening in the United Kingdom [49].
Displayed are 20-year absolute risks for incidence (including overdiagnosis) and mortality with and without screening. Overdiagnosis is set to 45% for prostate
cancer and 22% for breast cancer, respectively (age 50 to 69 years). Mortality reduction is set to be 20% for both cancers (age 55 and 74 years). For prostate
cancer, the estimates are based on the observed incidence and mortality in 1998 (before any widespread use of prostate-specific antigen (PSA)) and for breast
cancer in 2007 (latest data available).
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the absence of disease; negative framing emphasizes the
presence of disease [65] (Figure 6). Based on the 20-year
risk for a woman in the UK to die of breast cancer, the risk
of dying from breast cancer with mammography screening
would be 15 per 1,000 women and 17 to 18 per 1,000
women without mammography screening [49]. Positive
framing would be that the number of women that will not
die from breast cancer rises from between 982 and 983 to
985 per 1,000 women with the addition of screening for
breast cancer [34,35]. An example of positive framing is il-
lustrated in Figure 6.
Women are not only overestimating their risk of breast
cancer, but also substantially overestimating the benefit of
mammography screening [67,69-71]. Over 50% of all
women asked thought mammography screening reduced
the risk of dying from breast cancer by at least 50% [67,69].
Further, women wanted to have balanced information and
share the decision with their physician [71], but many re-
ported they were never provided information on false posi-
tives and side effects [71]. A report from Norway, where
women are invited with a prescheduled time and date of a
screening mammography appointment, showed that if the
invitation letter included an information leaflet aimed at en-
abling women to make a free and informed choice, the pre-
scheduled appointment undermined the option of not
participating [72]. The authors concluded that the current
recruitment procedures gave priority to screening uptake at
the expense of informed choice [72]. Thus, the principle of
informed choice might be in jeopardy [72].
Conclusion
Women should be correctly informed about the benefits
and harms of mammography screening (Figures 1 and 2).
A comprehensible way of communicating information on
benefits and harms of mammography screening is pre-
sented in Figure 1: among 1,000 women who start screen-
ing at age 50 and are screened for 20 years, 2 to 3 will
avoid dying from breast cancer and 200 women will have
at least one false positive test, 30 will undergo a biopsy, 3
will be diagnosed with an interval cancer, and breast can-
cer will be overdiagnosed in 15.
In an era of limited resources for health care and pre-
ventive services, we need to scrutinize our efforts in
screening and prevention. One of the overarching goals
Figure 6 Positive framing. Out of 1,000 women aged 50 to 69 years invited every second year, 781 are alive with screening and the same
number without screening over the course of 20 years. Correspondingly, 985 women and 982 to 983 women without screening will not die of
breast cancer aged 55 to 74 years. Negative framing: out of 1,000 women aged 50 to 69 years invited every second year, 204 women will die
with screening and the same number without screening. Correspondingly, 15 women with screening and 17 to 18 women without screening
will die of breast cancer between 55 and 74 years old. Number of women dying among women aged 55 to 74 years is based on the observed
mortality rates in England and Wales in 2007 [68]. The number of women dying over a 20-year period is estimated by summing the mortality
rates for the ages 55 to 74 [68].
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of screening is the reduction of incidence or mortality of
disease. Currently, we do recommend some screening
services (such as mammography), while others are de-
bated or discouraged (such as prostate-specific antigen
screening for prostate cancer or aspirin for primary pre-
vention of cardiovascular disease and premature death).
However, as Figures 4 and 5 show, these differences in
recommendations do often not reflect differences in ef-
fectiveness or harms between the different tests [49,62].
Abbreviation
DCIS: Ductal carcinoma in situ.
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